GLP-1s for PMOS

If you have a PCOS diagnosis, what you have is now formally called PMOS (polyendocrine metabolic ovarian syndrome), the new name confirmed by global consensus in May 2026. The diagnostic criteria did not change. The clinical condition did not change. The 2026 Lancet rename consensus also consolidated the evidence that PMOS is centrally metabolic, including the figures that approximately 85 percent of people with PMOS overall, and approximately 75 percent at a lean body weight, have insulin resistance. That metabolic core is the part of PMOS that GLP-1 receptor agonists most directly engage with.

GLP-1 receptor agonists, the medication class that includes semaglutide and tirzepatide, are increasingly prescribed to people with PMOS. The prescribing curve has moved faster than the PMOS-specific trial evidence. Both things can be true at once: the existing PMOS-specific trials are small, and the mechanism is compelling enough that the field is actively rethinking how it categorises this class within PMOS care.

This is an evidence-page article. It is structured by what the evidence currently supports, what is emerging, and what remains limited. It is not a prescription. Decisions about whether to start, continue, or stop a GLP-1 receptor agonist belong with a clinician who can evaluate the full picture.

A note on disclosures before reading further

The 2026 Lancet rename consensus is the strongest current summary source on the metabolic centrality of PMOS, and is cited in this article. Several individual authors of that consensus declared honoraria from pharmaceutical companies with adjacent commercial interests, including Novo Nordisk and Eli Lilly (the manufacturers of semaglutide and tirzepatide respectively), alongside Astellas, Ferring, Gedeon Richter, Bayer, and Exeltis. The consensus itself was not pharma-funded; funding came from the Australian National Health and Medical Research Council, Verity, and the AE-PCOS Society. Author honoraria of this kind are standard for senior endocrinology researchers and are disclosed transparently in the paper.

This is named here because the article that follows is centrally about GLP-1 medications. Pharma involvement in the broader PMOS evidence base is part of the context every reader of this article should hold. It is not a reason to discount the clinical data. It is a reason to read with appropriate care.

What GLP-1 receptor agonists are, and what they do

GLP-1 (glucagon-like peptide 1) is a gut hormone released after meals. It signals insulin release from the pancreas, slows gastric emptying, and acts in the brain to reduce appetite. GLP-1 receptor agonists are medications that mimic this hormone, sustaining its signal over the course of a week or longer in modern formulations.

The medications most relevant to current PMOS care:

• Semaglutide. Brand names Ozempic (for type 2 diabetes) and Wegovy (for chronic weight management). Weekly subcutaneous injection or daily oral form. Approved for diabetes in 2017 and for weight management in 2021.
• Tirzepatide. Brand names Mounjaro (diabetes) and Zepbound (weight management). A dual GLP-1 and GIP receptor agonist (acting on a second incretin pathway as well). Weekly subcutaneous injection. Approved for diabetes in 2022 and for weight management in 2023. Produces greater weight reduction than semaglutide on average in head-to-head data.
• Liraglutide. Brand name Saxenda. Daily subcutaneous injection. Older in the class and less commonly used in current PMOS practice.

The pathways relevant to PMOS run through three channels: improved insulin sensitivity (which reduces the insulin-driven ovarian androgen production that is central to PMOS), reduction in body weight where that is clinically indicated, and possibly direct effects in reproductive tissues, where GLP-1 receptors have been identified. The mechanism page on insulin resistance in PMOS covers the first channel in depth.

What the evidence currently supports

The structure of this section follows the evidence-page convention: claims sit at the strength their sources support, and the source strength is named alongside the claim.

Weight reduction is consistent and substantial. In the general obesity literature (STEP-1 for semaglutide, SURMOUNT-1 for tirzepatide), participants on full dose lose approximately 15 percent of body weight on semaglutide and approximately 22 percent on tirzepatide over 68 to 72 weeks. PMOS-specific trials are smaller but show consistent direction. Source strength: high (Tier 3 to Tier 4 in the Cyster evidence hierarchy).

Insulin sensitivity improves. HOMA-IR and fasting insulin markers improve on GLP-1 receptor agonists in PMOS-specific trials. The improvement is partly weight-mediated and partly direct. Source strength: medium-high (multiple small RCTs in PMOS plus the broader metabolic evidence base).

Menstrual cycle regularity often improves. Restoration of ovulatory cycles has been documented in multiple PMOS trials of liraglutide and semaglutide. The effect varies between participants and between trials. Source strength: medium (consistent direction in small trials; larger purpose-built PMOS trials are still ongoing).

Androgen markers decrease modestly. Free testosterone and the free androgen index decrease in many trial participants. The effect size is smaller than for weight or insulin markers and is more variable. Source strength: medium (smaller effect, consistent direction).

What is emerging

This section covers claims with active research interest, smaller current evidence base, or recent reframings that have not yet hardened into guideline endorsement.

The "PMOS as a complication of obesity-driven insulin resistance" reframing. A 2025 perspective in Expert Review of Endocrinology and Metabolism, alongside discussion in the broader endocrinology literature, has proposed that a substantial fraction of PMOS pathology can be understood as flowing through obesity-driven insulin resistance, and therefore as responsive to incretin-based therapies in ways earlier interventions could not reach. The 2026 Lancet rename consensus does not formally endorse this framing as the primary lens for the condition; it does centre insulin resistance as a defining mechanism. Source strength: emerging (perspective and review, not consensus).

This reframing is not universally accepted. It does not fit lean PMOS, where insulin resistance is present in roughly 75 percent of cases (Lancet 2026) without an obesity driver. It also does not fit phenotypes where androgen excess is the dominant feature and metabolic dysfunction is secondary. The pillar on lean PMOS covers the population this reframing does not cleanly describe.

Tirzepatide in PMOS specifically. Tirzepatide has the least PMOS-specific trial data of the three medications in this article. Case series, retrospective cohorts, and one pilot RCT exist. The rationale for use in PMOS is largely extrapolated from the larger SURMOUNT trial program in obesity. Source strength: limited for PMOS specifically; medium for the general weight and metabolic effects.

Direct GLP-1 receptor effects in reproductive tissues. GLP-1 receptors have been identified in ovarian and uterine tissue. Whether engaging these receptors contributes to PMOS-relevant outcomes (e.g., cycle regularity, androgen patterns) independently of weight and insulin effects is an open research question. Source strength: emerging mechanistic interest, not yet outcome-anchored.

Longer-term PMOS-specific outcomes. Most published PMOS-specific trials are short (12 to 52 weeks). What happens to PMOS-relevant outcomes (fertility, androgenic features, cycle patterns) over multi-year continuous treatment, and what happens after discontinuation, is not well-characterised in PMOS-specific data. The general obesity literature suggests weight regain after discontinuation is common; PMOS-specific follow-up is sparse. Source strength: limited.

What is limited or unresolved

This section covers areas where the evidence does not support a confident answer.

Use in lean PMOS without comorbidity. PMOS-specific trial evidence in normal-BMI populations without a separate obesity or diabetes indication is sparse. Reasoning for use in this group is mechanism-extrapolated rather than trial-anchored. Practice varies considerably between clinics. Source strength: limited.

Pregnancy safety. Animal studies have shown fetal growth restriction and embryotoxicity at clinically relevant doses. Human data are reassuring so far but underpowered: small registries with few exposures cannot rule out a meaningful increase in malformations. The current standard of care is consistent contraception during GLP-1 therapy and a washout period before conception attempts (approximately two months for semaglutide, reflecting roughly five half-lives). Source strength: animal data established; human data limited but accumulating.

Discontinuation patterns and PMOS outcomes. Weight regain after stopping GLP-1 therapy is well-documented in the general obesity literature. The PMOS-specific implication, that metabolic and cycle improvements driven by the medication will partially reverse with cessation, is consistent with the mechanism but not extensively trial-documented. The practical implication is that this class functions as chronic therapy in most cases, not as a defined course of treatment. Source strength: medium for the general weight pattern; limited for PMOS-specific outcomes after cessation.

Mental health signals. Early post-marketing reports raised concern about suicidal ideation. Larger analyses, including a 2024 JAMA Internal Medicine post-hoc of the STEP trials and a European Medicines Agency review, did not find an increase in suicide death attributable to GLP-1 use at the population level. PMOS already carries elevated baseline rates of depression and anxiety, so individual mood monitoring during initiation and dose escalation is appropriate even when the population-level signal is reassuring. Source strength: medium (large analyses reassuring on hard outcome; individual experience varies).

Lean mass and body composition. Body composition data from STEP-1 and SURMOUNT-1 show that approximately 15 to 17 percent of total weight lost is lean mass, with the remainder fat mass. Whether resistance training and adequate protein intake during treatment meaningfully changes this ratio is plausible but not extensively trial-tested. Source strength: medium.

Where this class fits in current PMOS care

The 2023 International Guideline does not endorse GLP-1 receptor agonists as standalone PMOS treatment outside of obesity or type 2 diabetes indications. The 2026 Lancet rename consensus does not change this. Two practical scenarios apply:

On-label for the comorbidity. A person with PMOS who also meets the criteria for chronic weight management (commonly framed as BMI of 30 or above, or BMI of 27 or above with at least one weight-related comorbidity) has an on-label indication. Comorbidities in this category include hypertension, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea, and several others. Insurance coverage is uneven but the prescribing pathway is clear.

Off-label for PMOS itself. A person with PMOS who does not meet a separate indication is in an off-label scenario. The PMOS-specific evidence exists but does not meet the threshold for guideline endorsement, and insurance coverage is rare. Practice varies considerably between clinics.

The fertility context adds a meaningful consideration. GLP-1 receptor agonists are not used during pregnancy. The recommended washout before conception attempts is approximately two months for semaglutide. For people actively trying to conceive or planning to in the near term, this timing is part of the calculus, not an afterthought.

A specific point on contraception during GLP-1 therapy in PMOS. Cycle regularisation can occur on these medications in people who were previously anovulatory. People who had not needed contraception because they were not ovulating may begin ovulating, sometimes without warning. Tirzepatide specifically can also delay gastric emptying enough to reduce absorption of oral contraceptive pills during initiation and dose escalation; the labelling recommends a non-oral or barrier method during that window. An unintended pregnancy on a GLP-1 receptor agonist is a different conversation than a planned one. This is worth raising with a clinician before starting, not after.

A note on access, cost, and supply

This is not a clinical question but it shapes the practical answer. List prices for semaglutide and tirzepatide in the United States in 2025 to 2026 sit at roughly $1,000 to $1,300 per month without insurance coverage, outside what most people can sustain indefinitely. Coverage decisions vary substantially: many plans cover the diabetes formulations (Ozempic, Mounjaro) but not the weight-management ones (Wegovy, Zepbound), and PMOS itself is not typically a covered indication.

Compounded versions of semaglutide and tirzepatide became widely available during the 2023 to 2024 supply shortages. Following the United States Food and Drug Administration’s removal of both medications from the official drug-shortage list, the compounding pathway has been substantially restricted as of 2025. The access landscape that existed for off-label PMOS prescribing through compounded preparations is mostly closed. International pricing varies, and access is materially different in jurisdictions with national formularies.

How to think about whether this fits, with a clinician

A practical framework for the personal conversation:

Strongest case for considering this class: PMOS plus an on-label indication for chronic weight management, with documented insulin resistance, after a reasonable trial of foundational interventions (sleep, meal composition, resistance training) and where indicated metformin. The on-label pathway, the metabolic benefit, and the more achievable coverage all line up.

Reasonable case: PMOS plus type 2 diabetes or significant prediabetes. The metabolic indication and the PMOS benefit run in the same direction.

Genuine conversation case: PMOS with documented insulin resistance, other approaches tried, and no separate on-label indication. This is off-label territory. The cost, access, fertility timing, and chronic-therapy framing all become inputs.

Less likely fit: Lean PMOS where the dominant phenotype is androgenic rather than metabolic. PMOS with current or historic disordered eating, where appetite suppression carries additional considerations. People actively trying to conceive in the near term, or in the 9 to 12 months preceding planned conception.

None of these is a prescription. The clinician conversation is where the framework meets the individual case.

A note on framing

GLP-1 receptor agonists sit in a part of PMOS care that is also a cultural conversation about body size, medicalisation, and access. This article is not the place to litigate that conversation in full. Two things worth naming briefly.

PMOS care that is built primarily around weight reduction has a long history of failing people, particularly people at a lean body weight whose PMOS is dismissed for not matching the expected body image, and people whose PMOS does not respond to weight-focused interventions. The metabolic case for engaging insulin resistance directly, including with GLP-1 receptor agonists in appropriate cases, is real, and is part of why the 2026 rename moved metabolic into the centre of the condition’s name.

PMOS care that defaults to GLP-1 prescription as the answer for every patient with PMOS, regardless of phenotype, lean status, fertility timing, or access reality, is a different failure mode. The evidence does not currently support that default. The on-label, off-label, and conversation-case framing above is meant to keep these two failure modes in view at once.

The honest summary, as of May 2026: GLP-1 receptor agonists are likely to become a more prominent part of PMOS care over the next several years, particularly as larger purpose-built PMOS trials report. For now, they are a useful option for the right person, not a default for every person with PMOS, and the safety considerations (especially around fertility, pregnancy, and discontinuation) deserve more weight than the cultural conversation around these medications typically gives them.